COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 685: Articles 6841-6850  | Next

Patients with affective disorders profit most from telemedical treatment: Evidence from a naturalistic patient cohort during the COVID-19 pandemic
Rohrmann, T., Praus, P., Proctor, T., Benedyk, A., Tost, H., Hennig, O., Meyer-Lindenberg, A., Wahl, A.-S.
10.1101/2022.06.23.22276832 — Posted: 2022-06-27
SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants: comparative assessments with New York State genomic surveillance data
Keyel, A., Russell, A., Plitnick, J., Rowlands, J. V., Rosenberg, E., Lamson, D. M., McDonough, K. A., St. George, K.
10.1101/2022.06.24.22276709 — Posted: 2022-06-26
Immunogenicity and safety of COVID-19 vaccine in lung cancer patients receiving anticancer treatment: A prospective multicenter cohort study
Nakashima, K., Ishida, M., Matsui, H., Yoshida, C., Nagai, T., Shiraga, M., Hiroshi, N., Otsuka, Y., Nakagama, Y., Kaku, N., Nitahara, Y., Kido, Y., Yoshio, H.
10.1101/2022.06.23.22276536 — Posted: 2022-06-26
Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., Uehara, T.
10.1101/2022.06.22.22276792 — Posted: 2022-06-26
Inflammasome activation and pulmonary viral loads define two distinct clinical outcomes in COVID-19
Sa, K. S., Amaral, L. A., Caetano, C. C., Becerra, A., Batah, S., Oliveira, I. M., Lopes, L. S., Almeida, L., Oliveira, S., Wada, D. T., Koenigkam-Santos, M., Martins, R. B., Rosales, R. R., Arruda, E., Fabro, A. T., Zamboni, D. S.
10.1101/2022.06.24.22276878 — Posted: 2022-06-26
The mental wellbeing of prison staff in England during the COVID-19 pandemic: a cross-sectional study
Johnson, L., Czachorowski, M., Gutridge, K., McGrath, N., Parkes, J., Plugge, E.
10.1101/2022.06.24.22276867 — Posted: 2022-06-26
Long-term immune persistence induced by two-dose BBIBP-CorV vaccine with different intervals, and immunogenicity and safety of a homologous booster dose in high-risk occupational population. Secondary Study Based on a Randomized Clinical Trial
Yao, T., Zhang, X., Mu, S., Guo, Y., Xu, X., Huo, J., Wei, Z., Liu, L., Li, X., Li, H., Xing, R., Feng, Y., Chen, J., Feng, L., Wang, S.
10.1101/2022.06.22.22276690 — Posted: 2022-06-26
Effect of hybrid immunity, school reopening, and the Omicron variant on trajectory of COVID-19 epidemic in India: A modelling study
Mozaffer, F., Cherian, P., Krishna, S., Wahl, B., Menon, G. I.
10.1101/2022.06.24.22276854 — Posted: 2022-06-26
Humoral Responses in the Omicron Era following Three-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients
McEvoy, C. M., Hu, Q., Abe, K. T., Yau, K., Oliver, M. J., Levin, A., Gingras, A.-C. M., Hladunewich, M., Yuen, D.
10.1101/2022.06.24.22276144 — Posted: 2022-06-26
Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism
Luo, S., Zhang, J., Kreutzberger, A. J. B., Eaton, A., Edwards, R. J., Jing, C., Dai, H.-Q., Sempowski, G. D., Cronin, K., Parks, R., Ye, A. Y., Mansouri, K., Barr, M., Pishesha, N., Williams, A. C., Francisco, L. V., Saminathan, A., Peng, H., Batra, H., Bellusci, L., Khurana, S., Alam, S. M., Montefiori, D. C., Saunders, K. O., Tian, M., Ploegh, H., Kirchhausen, T., Chen, B., Haynes, B. F., Alt, F. W.
10.1101/2022.06.26.497634 — Posted: 2022-06-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).